The CANTOS trial one important step for clinical cardiology but a giant leap for vascular biology

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 37, Issue 11, 2017, Pages e174-e177

  Baylis, Richard A ^a,b   Gomez, Delphine ^c,d   Mallat, Ziad ^e,f   Pasterkamp, Gerard ^g   Owens, Gary K ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Department of Biochemistry and Molecular Genetics ^*  (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CANAKINUMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; ARTICLE; ATHEROSCLEROSIS; CARDIOLOGY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); FATALITY; HUMAN; INFLAMMATION; METABOLIC PARAMETERS; NONHUMAN; OUTCOME ASSESSMENT; PRECLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT FAILURE; VASCULAR BIOLOGY; CORONARY ARTERY DISEASE; IMMUNOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ATHEROSCLEROSIS; CARDIOLOGY; CLINICAL TRIALS, PHASE III AS TOPIC; CORONARY ARTERY DISEASE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85044025259     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.117.310097     Document Type: Article

References (25)

1. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-1131. doi: 10.1056/NEJMoa1707914.
2. Harrington RA. Targeting inflammation in coronary artery disease. N Engl J Med. 2017;377:1197-1198. doi: 10.1056/NEJMe1709904.
3. Pasterkamp G, den Ruijter HM, Libby P. Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease. Nat Rev Cardiol. 2017;14:21-29. doi: 10.1038/nrcardio.2016.166.
4. Kanwar SS, Stone GW, Singh M, Virmani R, Olin J, Akasaka T, Narula J. Acute coronary syndromes without coronary plaque rupture. Nat Rev Cardiol. 2016;13:257-265. doi: 10.1038/nrcardio.2016.19.
5. Franck G, Mawson T, Sausen G, et al. Flow perturbation mediates neutrophil recruitment and potentiates endothelial injury via TLR2 in mice: Implications for superficial erosion. Circ Res. 2017;121:31-42. doi: 10.1161/CIRCRESAHA.117.310694.
6. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-235. doi: 10.1056/NEJMoa1002358.
7. Ridker PM. How common is residual inflammatory risk Circ Res. 2017;120:617-619. doi: 10.1161/CIRCRESAHA.116.310527.
8. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504. doi: 10.1056/NEJMoa040583.
9. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207. doi: 10.1056/NEJMoa0807646.
10. Gomez D, Shankman LS, Nguyen AT, Owens GK. Detection of histone modifications at specific gene loci in single cells in histological sections. Nat Methods. 2013;10:171-177. doi: 10.1038/nmeth.2332.
11. Herder C, Dalmas E, Böni-Schnetzler M, Donath MY. The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol Metab. 2015;26:551-563. doi: 10.1016/j.tem.2015.08.001.
12. Choudhury RP, Birks JS, Mani V, et al. Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance. J Am Coll Cardiol. 2016;68:1769-1780. doi: 10.1016/j.jacc.2016.07.768.
13. Rissanen A, Howard CP, Botha J, Thuren T; Global Investigators. Effect of anti-IL-1 antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: Results of a randomized, placebo-controlled trial. Diabetes Obes Metab. 2012;14:1088-1096. doi: 10.1111/j.1463-1326.2012.01637.x.
14. Sager HB, Heidt T, Hulsmans M, Dutta P, Courties G, Sebas M, Wojtkiewicz GR, Tricot B, Iwamoto Y, Sun Y, Weissleder R, Libby P, Swirski FK, Nahrendorf M. Targeting interleukin-1 reduces leukocyte production after acute myocardial infarction. Circulation. 2015;132:1880-1890. doi: 10.1161/CIRCULATIONAHA.115.016160.
15. Alexander MR, Moehle CW, Johnson JL, Yang Z, Lee JK, Jackson CL, Owens GK. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest. 2012;122:70-79. doi: 10.1172/JCI43713.
16. Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM, Swiatlowska P, Newman AA, Greene ES, Straub AC, Isakson B, Randolph GJ, Owens GK. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med. 2015;21:628-637. doi: 10.1038/nm.3866.
17. Cherepanova OA, Gomez D, Shankman LS, et al. Activation of the pluripotency factor OCT4 in smooth muscle cells is atheroprotective. Nat Med. 2016;22:657-665. doi: 10.1038/nm.4109.
18. Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118:692-702. doi: 10.1161/CIRCRESAHA. 115.306361.
19. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045-2051. doi: 10.1161/ATVBAHA.108.179705.
20. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 2010;10:36-46. doi: 10.1038/nri2675.
21. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: A dynamic balance. Nat Rev Immunol. 2013;13:709-721. doi: 10.1038/nri3520.
22. Randolph GJ. Emigration of monocyte-derived cells to lymph nodes during resolution of inflammation and its failure in atherosclerosis. Curr Opin Lipidol. 2008;19:462-468. doi: 10.1097/MOL.0b013e32830d5f09.
23. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, CANTOS Trial Group. Effect of interleukin-1 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;
24. Bhaskar V, Yin J, Mirza AM, Phan D, Vanegas S, Issafras H, Michelson K, Hunter JJ, Kantak SS. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. Atherosclerosis. 2011;216:313-320. doi: 10.1016/j.atherosclerosis.2011.02.026.
25. Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842-847. doi: 10.1126/science.aag1381.